Incyte (INCY) Stock Price, News & Analysis

Company Overview

Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for oncology and inflammatory diseases. Founded in 1991 and headquartered in Wilmington, Delaware, the company conducts research in areas including oncology, hematology, immunology and dermatology.

Incyte’s commercial portfolio includes Jakafi (ruxolitinib), a treatment for certain myelofibrosis, polycythemia vera and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib) for selected cancers involving abnormal FGFR signaling. The company also markets other therapies, including Minjuvi/Monjuvi (tafasitamab) for certain adults with relapsed or refractory diffuse large B-cell lymphoma, and Zynyz (retifanlimab) for a type of advanced squamous cell carcinoma.

Incyte develops medicines independently and through collaborations with pharmaceutical and biotechnology companies. Its products and research activities serve patients and healthcare providers in the United States and international markets, with the company maintaining operations and partnerships across North America, Europe and other regions. Hervé Hoppenot serves as Incyte’s chief executive officer.

Key Stats

• Today's Range: $122.60 to $124.35
• 50-Day Range: $114.23 to $129.93
• 52-Week Range: $81.09 to $132.60
• Volume: 53,781 shs
• Average Volume: 1.71 million shs
• Market Capitalization: $24.72 billion
• P/E Ratio: 15.57
• Dividend Yield: N/A
• Price Target: $124.05
• Consensus Rating: Moderate Buy

Incyte Stock Analysis - MarketRank™

Incyte scored higher than 68% of companies evaluated by MarketBeat, and ranked 262nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Incyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 1 strong buy rating, 11 buy ratings, 12 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Incyte is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Incyte has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 200.38%

Earnings Growth

Earnings for Incyte are expected to grow by 200.38% in the coming year, from $2.64 to $7.93 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incyte is 15.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incyte is 15.70, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.84.

Price to Earnings Growth Ratio

Incyte has a PEG Ratio of 3.66. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Incyte has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.51% of the float of Incyte has been sold short.

Short Interest Ratio / Days to Cover

Incyte has a short interest ratio ("days to cover") of 7.69.

Change versus previous month

Short interest in Incyte has recently decreased by 0.26%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incyte does not currently pay a dividend.

Dividend Growth

Incyte does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.14

News Sentiment

Incyte has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Incyte this week, compared to 8 articles on an average week.

Search Interest

Only 10 people have searched for INCY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

13 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,361,428.00 in company stock.

Percentage Held by Insiders

16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 9/11/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/16/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INCY
• CIK: 879169
• Web: www.incyte.com
• Phone: (302) 498-6700
• Fax: 302-425-2750
• Employees: 2,844
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Incyte: $124.05
• High Price Target: $155.00
• Low Price Target: $90.00
• Potential Upside/Downside: +1.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.52
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.85
• Trailing P/E Ratio: 15.57
• Forward P/E Ratio: 46.19
• P/E Growth: 3.66
• Net Income: $1.29 billion
• Net Margins: 27.71%
• Pretax Margin: 33.81%
• Return on Equity: 29.93%
• Return on Assets: 22.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.59
• Quick Ratio: 4.51

Sales & Book Value

• Annual Sales: $5.14 billion
• Price / Sales: 4.81
• Cash Flow: $5.98 per share
• Price / Cash Flow: 20.39
• Book Value: $26.32 per share
• Price / Book: 4.63

Miscellaneous

• Outstanding Shares: 202,700,000
• Free Float: 169,861,000
• Market Cap: $24.72 billion
• Optionable: Optionable
• Beta: 0.77